首页> 外国专利> ENDOGENOUS RETROVIRUS TRANSCRIPTION AS A MARKER FOR PRIMATE NAÏVE PLURIPOTENT STEM CELLS

ENDOGENOUS RETROVIRUS TRANSCRIPTION AS A MARKER FOR PRIMATE NAÏVE PLURIPOTENT STEM CELLS

机译:内源性逆转录转录作为主要幼稚多能干细胞的标记

摘要

The present invention relates to the use of one or more type 7 long terminal repeat (LTR7) nucleic acid sequences of type H human endogenous retroviruses (HERVH) ("LTR7/HERVH nucleic acid sequences") for identifying primate naive pluripotent stem cells. The invention is directed to the use of LTR7/HERVH nucleic acid sequences as a marker, wherein LTR7/HERVH-associated transcription is used as a marker for primate naive pluripotent stem cells. The invention also relates to a reporter construct comprising LTR7/HERVH nucleic acid sequences in addition to the use of said reporter, in particular for optimizing culture conditions for naïve primate pluripotent stem cells. The invention also relates to a cell growth medium for cultivation of primate naive pluripotent stem cells that preferably exhibit elevated levels of LTR7/HERVH-associated transcription in comparison to control cells.
机译:本发明涉及一种或多种H型人内源逆转录病毒(HERVH)的7型长末端重复(LTR7)核酸序列(“ LTR7 / HERVH核酸序列”)在鉴定灵长类幼稚多能干细胞中的用途。本发明涉及LTR7 / HERVH核酸序列作为标志物的用途,其中LTR7 / HERVH相关的转录用作灵长类幼稚多能干细胞的标志物。本发明还涉及除所述报道子的用途外还包含LTR7 / HERVH核酸序列的报道子构建体,特别是用于优化幼稚的灵长类多能干细胞的培养条件。本发明还涉及用于培养灵长类幼稚多能干细胞的细胞生长培养基,与对照细胞相比,所述干细胞优选表现出升高的LTR7 / HERVH相关转录水平。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号